含有SET和MYND结构域的(SMYD)基因家族包含一组编码赖氨酸甲基转移酶的基因。本研究旨在阐明SMYD家族成员表达水平与消化系统恶性肿瘤预后及免疫浸润的关系。
■TheOncomine,Ualcan,Kaplan-Meier绘图仪,cBioPortal,Metascape,和TIMER数据库和工具用于分析SMYD家族mRNA表达的相关性，临床分期,TP53突变状态,预后价值，基因突变,食管癌（ESCA）患者的免疫浸润，肝细胞癌（LIHC），胃腺癌（STAD）。
■在ESCA中，SMYD2/3/4/5的mRNA表达与发病率显著相关,SMYD2/3的临床阶段，SMYD2/3/4/5的TP53突变状态，SMYD2/4/5的总生存期（OS），SMYD1/2/3/4无复发生存期（RFS）。在LIHC,SMYD1/2/3/4/5的mRNA表达与发病率显著相关,SMYD2/4/5的临床分期，具有TP53突变状态的SMYD3/5，使用操作系统的SMYD2/3/4/5，以及带有RFS的SMYD3/5。在STAD中,SMYD2/3/4/5的mRNA表达与发病率显著相关,SMYD1/4的临床分期，SMYD1/2/3/5的TP53突变状态，使用操作系统的SMYD1/3/4，以及带有RFS的SMYD1/3。此外，SMYD家族突变相关基因在ESCA中的功能,LIHC,STAD患者主要与通路有关，如线粒体基因表达，线粒体基质，和线粒体翻译。SMYD家族基因的表达与6种免疫细胞类型和8种免疫检查位点的浸润显著相关。
■SMYD家族基因在消化系统的恶性肿瘤中差异表达并经常突变（ESCA，LIHC,和胃癌）。它们是预测预后的潜在标志物，在免疫和靶向治疗中具有重要意义。
UNASSIGNED: The SET and MYND domain-containing (
SMYD) gene family comprises a set of genes encoding lysine methyltransferases. This study aimed to clarify the relationship between the expression levels of
SMYD family members and the prognosis and immune infiltration of malignant tumors of the digestive system.
UNASSIGNED: The Oncomine, Ualcan, Kaplan-Meier Plotter, cBioPortal, Metascape, and TIMER databases and tools were used to analyze the correlation of
SMYD family mRNA expression, clinical stage, TP53 mutation status, prognostic value, gene mutation, and immune infiltration in patients with esophageal carcinoma (ESCA), liver hepatocellular carcinoma (LIHC), and stomach adenocarcinoma (STAD).
UNASSIGNED: In ESCA, the mRNA expression of SMYD2/3/4/5 was significantly correlated with the incidence rate, that of SMYD2/3 with the clinical stage, that of SMYD2/3/4/5 with TP53 mutation status, that of SMYD2/4/5 with overall survival (OS), and that of SMYD1/2/3/4 with relapse-free survival (RFS). In LIHC, the mRNA expression of SMYD1/2/3/4/5 was significantly correlated with the incidence rate, that of SMYD2/4/5 with the clinical stage, that of SMYD3/5 with TP53 mutation status, that of SMYD2/3/4/5 with OS, and that of SMYD3/5 with RFS. In STAD, the mRNA expression of SMYD2/3/4/5 was significantly correlated with the incidence rate, that of SMYD1/4 with the clinical stage, that of SMYD1/2/3/5 with TP53 mutation status, that of SMYD1/3/4 with OS, and that of SMYD1/3 with RFS. Furthermore, the function of
SMYD family mutation-related genes in ESCA, LIHC, and STAD patients was mainly related to pathways, such as mitochondrial gene expression, mitochondrial matrix, and mitochondrial translation. The expression of
SMYD family genes was significantly correlated with the infiltration of six immune cell types and eight types of immune check sites.
UNASSIGNED: SMYD family genes are differentially expressed and frequently mutated in malignant tumors of the digestive system (ESCA, LIHC, and gastric cancer). They are potential markers for prognostic prediction and have important significance in immunity and targeted therapy.
PDF(Pubmed)